Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRT12396 in Polycythemia Vera and Myelofibrosis
NCT07469891Phase 1Recruiting
- Sponsor
- Prelude Therapeutics
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of PRT12396 in polycythemia vera (PV) and myelofibrosis (MF) (2 arms), sponsored by Prelude Therapeutics. Primary endpoints: Dose Limiting Toxicity at 4 weeks, Incidence and severity of Adverse events at 2 years and 2 more. Started Apr 2026; status: recruiting.
02
Drugs
PRT12396
03
Conditions
polycythemia vera (PV)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT07469891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07469891.